Analysts expect Biomarin Pharmaceutical Inc to report revenue of 981.93 M for Q3 26, against a range of 892.24 M to 1.07 B. The most recent reported quarter, Q2 26, came in at 989.71 M, a 4.0% beat against the 952.04 M consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 745.74 M | 747.00 M | 745.14 M | 825.00 M | 776.13 M | 874.57 M | 766.00 M | 989.71 M | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 745.39 M | 794.92 M | 822.86 M | 798.48 M | 872.25 M | 810.38 M | 734.95 M | 991.16 M | 1.07 B | 1.15 B | 1.09 B | 1.11 B | 1.13 B | 1.27 B | 1.09 B | 1.18 B | ||||||||||
| Low Estimate | 624.55 M | 681.11 M | 687.20 M | 691.84 M | 774.58 M | 753.69 M | 684.60 M | 912.92 M | 892.24 M | 1.00 B | 978.77 M | 1.04 B | 1.06 B | 1.14 B | 1.00 B | 1.06 B | ||||||||||
| Consensus Estimate | 684.97 M | 738.01 M | 755.03 M | 745.16 M | 823.41 M | 782.03 M | 709.78 M | 952.04 M | 981.93 M | 1.08 B | 1.03 B | 1.07 B | 1.09 B | 1.20 B | 1.05 B | 1.12 B |
Analysts expect Biomarin Pharmaceutical Inc to report earnings per share of 1.38 for Q3 26, against a range of 1.27 to 1.49. The most recent reported quarter, Q2 26, came in at 1.20, a 21.2% beat against the 0.99 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.55 | 0.64 | 0.95 | 1.23 | -0.16 | -0.24 | 0.76 | 1.20 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | 0.55 | 0.60 | 0.72 | 0.97 | -0.25 | 0.20 | 0.69 | 1.06 | 1.49 | 1.78 | 1.65 | 1.61 | 1.46 | 2.21 | 2.21 | 2.25 | ||||||||||
| Low Estimate | 0.49 | 0.50 | 0.62 | 0.81 | -0.29 | 0.16 | 0.61 | 0.92 | 1.27 | 1.64 | 1.43 | 1.39 | 1.30 | 1.89 | 2.07 | 1.99 | ||||||||||
| Consensus Estimate | 0.52 | 0.55 | 0.67 | 0.89 | -0.27 | 0.18 | 0.65 | 0.99 | 1.38 | 1.71 | 1.54 | 1.50 | 1.38 | 2.05 | 2.14 | 2.12 |
Pull Wall Street consensus for Biomarin Pharmaceutical Inc (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=BMRN&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "BMRN", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=BMRN&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();